Document is current
Any future updates will be listed below
-
Authors
Esposito, Maria https://orcid.org/0000-0002-4773-6993
Morón-Ocaña, Juan Manuel https://orcid.org/0000-0002-9589-6318
Gupta, Aditya K. https://orcid.org/0000-0002-8664-7723
Galván, Jordi https://orcid.org/0000-0002-2435-2129
Bentohami, Ayoub
Freischläger, Frank https://orcid.org/0009-0006-8613-5302
-
Funding
Funding for this research was provided by:
Almirall S.A.
- License Information
-
More Information
Article History
Received: 14 May 2026
Accepted: 17 June 2026
First Online: 1 July 2026
Declarations
:
: Maria Esposito declares to have served as speaker or board member for Abbvie, Almirall, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi-Regeneron, UCB. Juan Manuel Morón-Ocaña declares no conflicts of interest. Aditya Gupta is a consultant for Almirall S.A. Jordi Galván and Ayoub Bentohami are employees of Almirall S.A. Frank Freischläger is co-founder and co-owner of Estimondo GmbH.
: The study protocols of the two phase III studies were reviewed and approved by ethics committees or local institutional review boards (independent ethics committee for trial MC2-01-C7: Ethikkommission der Ärztekammer, Hamburg, Weidestraße 122b, 22083 Hamburg, Germany; central institutional review board for trial MC2-01-C2: Quorum, 1501 Fourth Ave, Ste 800, Seattle, WA 98101). Both studies were conducted according to the 1964 Declaration of Helsinki and its subsequent amendments. All patients provided written informed consent to participate in the phase III studies.
